Arun Uro

New urodynamics technology: Wireless, Tubeless UDS with @bright_uro supported by years of research from @CleClinicUro. Glean system now FDA approved coming to Europe - stay tuned. #EAU2026

Every post from @supriyasahuias ji proves why there could be no better candidate for UN Champion of the Earth than her. A mix bag of happy jealousy as I see her department in Tamil Nadu take phenomenal strides in environment conservation, and growth. What truly is amazing is also the way the State Government has balanced Industry and Environment.

🔬 Innovation spotlight: Early apical release in HoLEP This technical modification reduced our operative time by 23 minutes average while improving continence outcomes. Sometimes the biggest advances come from small technical details and simple ideas. Key: Carefully release apex at the beggining of the operation, protect the external urinary sphincter → cleaner plane, less trauma. #HoLEP #TechnicalTip #UrologyInnovation #ProstateSurgery

The injustice to Tamilnadu can't be articulated any better @TThenarasu @ptrmadurai @TRBRajaa PS : thanks to @puram_politics for this powerful chart

ESMO 2026 reshapes advanced prostate cancer care From de novo mCSPC to molecularly defined mCRPC, treatment is now earlier, intensified, and genotype-driven. 🧬 mCSPC 🟢 Low volume → ADT + ARPI is standard 🟣 High volume → Fit patients: ADT + docetaxel + ARPI (triplet) → Unfit for docetaxel: ADT + ARPI ⚠️ ADT alone is obsolete except in frail patients ❌ Zoledronic acid / denosumab NOT recommended in mCSPC 🧠 Relapsed mCSPC • Low volume: ADT + ARPI • High volume: ADT + ARPI ± docetaxel (selected) 🧬 mCRPC without known mutations • Prior ADT only: ARPI or docetaxel • Post-ARPI: docetaxel or ¹⁷⁷Lu-PSMA-617 • Post-docetaxel + ARPI: ¹⁷⁷Lu-PSMA-617 or cabazitaxel 🧬 mCRPC with genetic alterations • BRCA: PARP inhibitor ± ARPI > chemotherapy • PALB2 / CDK12: selective PARPi use • dMMR: PD-1 / PD-L1 inhibitor early • Aggressive variant / NEPC: platinum-based chemotherapy 🦴 Bone health ✅ All mCRPC with bone mets must receive BPA ❌ Not for mCSPC 💡 Takeaway Earlier intensification. Mandatory genomics. Radioligand therapy mainstream. 🔖 Save this for daily OPD decisions 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #ProstateCancer #GUOncology @OncoAlert @myesmo @esmo_open @asco @Annals_Oncology

@lkeshav1965 @usioffice Congrats sir

Assumed charge as President of Urological society of India at Indore @usioffice

What it means ❤️‍🔥

Dear friends, I have something important to tell you. In December 2024, 'researchers' from multiple Indian Government Homeopathy institutions along with 'researchers' from Israeli Homeopathy institutes, published a randomized controlled trial that concluded that use of Homeopathic formulations in children during first 24 months of life reduced infections and antibiotics use compared to 'standard of care.' This was published in the prestigious European Journal of Pediatrics. The study was viral. It was all over the media and news here in South India and also in some National media and was Whatsapp 'proof' of Homeopathy being better than modern medicine in infants. The study was used to promote anti-vaccine sentiments and Homeopathy products in South India. Homeopaths hailed the study as 'path breaking' - also because the Ayush Ministry and Government Homeopathy practitioners were study authors involved in it. I read the study. I am trained in advanced statistics and research writing. The study was utter nonsense. And fraud. It looked like the authors did not even actually perform the study. I really doubted whether any patients were involved at all. I wrote a letter to the editor of the journal, asking him to kindly review the paper and investigate 'scientific integrity' and ethics. And after nearly 10 months of investigations by the Journal, Publisher and Research Integrity Team, we were proven correct. The paper was fraud and now it has been RETRACTED. @RetractionWatch The lesson here is that, if people really did understand what Homeopathy is and what its practitioners are, it is easy to find that it is clearly fraud. There is nothing in Homeopathy that works. It is unscientific utter nonsense. Every positive study on Homeopathy is mostly published in 'Homeopathy' journals. Sometimes, it infiltrates a real, valid journal (like in this case) and then it gets retracted because the scientific community is always alert. There are many such instances: See - pmc.ncbi.nlm.nih.gov/articles/PMC12… and nature.com/articles/s4159… and nature.com/articles/s4159… The worst part here is that all these Homeopathy practitioners who are authors of the study are working in Indian Govt. public health sector - meaning, their salary is paid from public funds and citizens taxes. These wastrels are eating away our hard earned money and using it to fund fraud. Who will stop these criminals? Even worse, the fraud, now retracted study was published as 'open access' in the European Journal of Pediatrics - which means, the authors paid £3090.00 GBP or $4990 USD, or €3990 EUR equivalent in INR to publish fraud. Where did they get this money from? Yes. Indian public tax money. Homeopathy needs to be booted out of this country. Parents, do not send your children to study Homeopathy even though India offers a 5 year course and gives them a "Dr." title at the end of it. They are not doctors. They are legitimized frauds and legalized quacks, as you can see from this retraction. "Homeopathy is a lively relic of the prescientific era. Not healthcare." @arifhussaintm Link: #author-information" target="_blank" rel="nofollow noopener">link.springer.com/article/10.100…

Why did Harvard University study Taj Hotel HR Management after 26/11 Terrorist attack? Very interesting observation by Prakash Belawadi sir

@sbinhamrii Is that Kitkat?

🤔 Check this out

@fgomsan @IrinaJaeger Agree with every word. Your videos are great learning for people starting HoLEP

Just read this piece in Urology Times... thanks and Merry Christmas @IrinaJaeger. I am so glad that my YouTube videos helped you to learn HoLEP! You are a true star now! urologytimes.com/view/inside-ho… @DrFernandoGomezSancha" target="_blank" rel="nofollow noopener">youtube.com/@DrFernandoGom…

Salim Ghouse

@kalanahareen Nice meeting you sir

AIE 2025 (Advancements in Endourology) Ahmedabad 🇮🇳 joined as invited international faculty

Last month,I was on a tour to Rajasthan. Was wondering what ails Indian Tourist Industry. Here r some of my observations: India has everything, except the basics. Ancient temples, centuries old-architectural marvels, wild mountains, a civilisation that breathes through food, festivals, stone and song. Yet travellers remember something else. 🫱 Filthy restrooms. 🫱 Journeys that collapse at the last mile. 🫱 Fleecing masked as hospitality, or a cringe-worthy servility to white skin. Both are ugly. Both are shameful. 🫱 Signage that vanishes, accessibility that never arrives. 🫱 Streets that turn unsafe after dusk. 🫱 Policing that watches, but does not care. “Incredible India” shines on billboards, but fades the moment one steps outside the frame. Tourism is not a slogan. It is cleanliness, safety especially for women,dignity, comfort, and ease. Until we fix the experience, not just market the postcard, India will be visited, but it will never be recommended.

Localised prostate cancer just changed. Again. ESMO 2026 brings clarity on who to observe, who to escalate, and which trials actually matter 👇 🧠 Diagnosis MRI before biopsy is standard High-resolution US is a valid alternative (RCT n=678) 🧭 Low risk Active surveillance is safe ProtecT 15-yr data shows similar survival vs RP/RT ☢️ Radiotherapy Shorter is better CHHiP ➜ moderate hypofractionation HYPO-RT-PC ➜ ultra-hypofractionation PACE-B ➜ SBRT works in selected IR disease 📈 High risk RT + long-term ADT saves lives SPCG-7 | NCIC/MRC Dose escalation improves OS (GETUG-AFU 18) 🚨 Very high-risk / cN1 RT + ADT + abiraterone is the new benchmark STAMPEDE delivers MFS + OS benefit 🔁 Biochemical recurrence Avoid routine adjuvant RT Early salvage RT preferred RADICALS-RT | RAVES | GETUG-AFU 17 High-risk BCR? Intensify EMBARK supports enzalutamide + ADT 🧠 Bottom line Risk-adapted care > overtreatment Imaging-driven decisions Escalate only when trials prove benefit 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #ProstateCancer #GUOncology @OncoAlert @myesmo @esmo_open @asco @OncBrothers

🚨 Prostate cancer care has changed fast. Here’s the 2025 snapshot. The new Lancet Seminar lays out how prostate cancer management has transformed across the disease spectrum 🌍🧬 🔍 Early disease Active surveillance is the default for low-risk tumors, avoiding overtreatment while maintaining excellent outcomes. MRI-first pathways improve detection of clinically significant cancer. ⚖️ Localized to high-risk Surgery and modern radiotherapy offer equivalent cancer control. Hypofractionation and SBRT shorten treatment without compromising efficacy. High-risk disease needs multimodality care. 🚀 Metastatic hormone-sensitive ADT alone is no longer enough. Doublet or triplet therapy with ARPIs ± docetaxel is now standard, with prostate RT benefiting low-volume disease. 🎯 mCRPC era Treatment is biology-driven: PARP inhibitors for HRR alterations, Lu-177 PSMA radioligand therapy after ARPI and taxanes, cabazitaxel preferred over ARPI sequencing. 🧠 Big takeaway Sequencing, patient selection, toxicity, and shared decision-making matter as much as drug choice. 📖 Valérie Fonteyne et al. Lancet 2025 A must-read, practice-defining review for every GU oncologist 🔖 #OncoTwitter #MedTwitter #ProstateCancer #GUOncology @TheLancet @myESMO @OncoAlert @ASCO

Had a wonderful night at Nadiad, thanks to the courtesy of @abhisingh82 . Had a great evening in the illustrious company of Mahesh Desai sir @drragoori @mallikuro7 @sbinhamrii @DocGauhar @AnilElhence

@fgomsan It was a pleasure watching you operate . Great learning

Live surgery at Ahmedabad, India

@ainuindia @sanprinarch @doctorvenki @MathisekaranT